Nebula Research & Development’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Nebula Research & Development’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-69,884	Closed	-$1.93M	–	463
2025 Q2	$1.93M	Buy	69,884 +31,570	+82%	+$804K	0.16%	199
2025 Q1	$851K	Buy	38,314 +8,793	+30%	+$181K	0.08%	421
2024 Q4	$584K	Sell	29,521 -9,483	-24%	-$216K	0.07%	494
2024 Q3	$975K	Buy	39,004 +23,934	+159%	+$583K	0.12%	297
2024 Q2	$281K	Buy	+15,070	New	+$282K	0.05%	621
2023 Q4	–	Sell	-13,686	Closed	-$238K	–	772
2023 Q3	$238K	Buy	+13,686	New	+$231K	0.13%	350

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nebula Research & Development's KNSA Position: Q3 2025 in Review

Nebula Research & Development sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 69,884 shares — an estimated $1.93M sold.

Nebula Research & Development first reported a position in KNSA in Q3 2023 and held it in 6 quarters. The position peaked at $1.93M in Q2 2025. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

Nebula Research & Development reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Nebula Research & Development sold 69,884 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $1.93M.
Nebula Research & Development first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and held it in 6 quarters.
Nebula Research & Development's Kiniksa Pharmaceuticals position peaked at $1.93M in Q2 2025.
204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.